Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the treatment of neurofibromatosis type
Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the treatment of neurofibromatosis type
-- Activation of four U.S. sites for Phase 1 clinical trial of PAS-004 to evaluate safety, dose, key biomarker data and preliminary efficacy ---- Plans to open three additional sites in Eastern Europe in the coming
-- Polymorph and Stereoisomer Patents when Issued Extend Portfolio to at least 2045 -- -- Polymorph and Stereoisomer Patent Filings Continue to Expand Patent Portfolio --SOUTH SAN FRANCISCO, Calif. and
- SEC Filing On December 28, 2023, Pasithea Therapeutics Corp. (the "Company") filed a Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company with the Secretary of State of